Skip to main content
  • Clinical
      |Clinical
    • Acute Coronary Syndromes
    • Cardiac Surgery
    • Covid-19
    • Heart Failure
    • Heart Health
    • Heart Rhythm
    • Hypertension
    • Interventional Cardiology
    • Mitral Valve
    • Pharmaceutics
    • Structural Heart Disease
    • TAVR
    • Tricuspid Valve
    • Vascular & Endovascular
  • Management
      |Management
    • Chest Pain Guidelines
    • Compensation
    • Economics
    • Education & Training
    • Legal News
    • Patient Care
    • Policy & Regulations
    • Professional Associations
    • Quality
    • Revenue
    • Staffing
  • Technology
      |Technology
    • AI
    • Cardiac Imaging
    • Cath Lab
    • CT
    • CVIS
    • ECG
    • Echo
    • EP Lab
    • Informatics
    • MRI
    • Nuclear Cardiology
    • Remote Monitoring
  • Videos
  • Conferences
      |Conferences
    • ACC
    • AHA
    • ASE
    • ASNC
    • ESC
    • EuroPCR
    • HFSA
    • HRS
    • HRS
    • SCAI
    • SCCT
    • SIIM
    • SNMMI
    • STS
    • TCT
    • VIVA
  • Custom Content
      |Custom Content
    • Experience Stories
    • Webinars & Videos
  • Subscribe
  • Forty Under 40 Award
      |Forty Under 40 Award
    • Class of 2026
    • Class of 2025

Search form

Home

News You Need to Know Today
Heart Health Highlights: FDA approves first anti-inflammatory drug for CVD | TAVR vs. surgery for obese patients
Friday, July 21, 2023
Link to Twitter Link to Facebook Link to Linkedin Link to Vimeo

Editor's Choice: Heart Health

FDA approves colchicine, the first anti-inflammatory drug for treating cardiovascular disease

The FDA's approval of colchicine, which is marketed and sold under the name Lodoco, is expected to have a big impact on cardiac care and outcomes.

READ MORE >
The U.S. Food and Drug Administration (FDA) priority review, the FDA has cleared the Agepha Pharma USA LLC's drug Lodoco (colchicine) as the first anti-inflammatory atheroprotective cardiovascular treatment. Colchicine prevents coronary artery plaque inflammation, heart inflammation. Colchicine for coronary artery disease. Colchicine for coronary inflammation FDA Approves Colchicine for Decreasing CV Events FDA Approves Colchicine for decreasing inflammation caused by coronary atherosclerosis.
Share on Twitter Share on Facebook Share on Linkedin

FDA approves colchicine, the first anti-inflammatory drug for treating cardiovascular disease

Share on Twitter Share on Facebook Share on Linkedin
The U.S. Food and Drug Administration (FDA) priority review, the FDA has cleared the Agepha Pharma USA LLC's drug Lodoco (colchicine) as the first anti-inflammatory atheroprotective cardiovascular treatment. Colchicine prevents coronary artery plaque inflammation, heart inflammation. Colchicine for coronary artery disease. Colchicine for coronary inflammation FDA Approves Colchicine for Decreasing CV Events FDA Approves Colchicine for decreasing inflammation caused by coronary atherosclerosis.
The FDA's approval of colchicine, which is marketed and sold under the name Lodoco, is expected to have a big impact on cardiac care and outcomes.
READ MORE >

FDA asked to investigate ‘eye-popping’ amount of caffeine in Logan Paul’s Prime energy drinks

Should an energy drink with more caffeine than five cans of soda be marketed to kids? Sen. Chunk Schumer shared his concerns in a new letter to FDA Commissioner Robert Califf, MD, a veteran cardiologist. 

READ MORE >
Sen. Chunk Schumer has asked the U.S. Food and Drunk Administration (FDA) to investigate the high amount of caffeine found in energy drinks sold by Prime, a beverage brand founded by YouTube personalities Logan Paul and KSI. According to Schumer, the “eye-popping 200 mg of caffeine” found in a single Prime energy drink is troubling, especially for a product marketed primarily to children.
Share on Twitter Share on Facebook Share on Linkedin

FDA asked to investigate ‘eye-popping’ amount of caffeine in Logan Paul’s Prime energy drinks

Share on Twitter Share on Facebook Share on Linkedin
Sen. Chunk Schumer has asked the U.S. Food and Drunk Administration (FDA) to investigate the high amount of caffeine found in energy drinks sold by Prime, a beverage brand founded by YouTube personalities Logan Paul and KSI. According to Schumer, the “eye-popping 200 mg of caffeine” found in a single Prime energy drink is troubling, especially for a product marketed primarily to children.
Should an energy drink with more caffeine than five cans of soda be marketed to kids? Sen. Chunk Schumer shared his concerns in a new letter to FDA Commissioner Robert Califf, MD, a veteran cardiologist. 
READ MORE >

TAVR vs. surgery among obese patients: What cardiologists need to know

Researchers tracked data from nearly 38,000 obese patients who underwent TAVR or SAVR, sharing their findings in a new meta-analysis. 

READ MORE >
doctor with overweight patient who may be treated with TAVR or surgery
Share on Twitter Share on Facebook Share on Linkedin

TAVR vs. surgery among obese patients: What cardiologists need to know

Share on Twitter Share on Facebook Share on Linkedin
doctor with overweight patient who may be treated with TAVR or surgery
Researchers tracked data from nearly 38,000 obese patients who underwent TAVR or SAVR, sharing their findings in a new meta-analysis. 
READ MORE >

FDA approves first cellular therapy to treat type 1 diabetes

The new therapy, made from the pancreatic cells of deceased donors, is designed to help adult type 1 diabetes with severe hypoglycemia go a year or longer without needing to take insulin. 

READ MORE >
The FDA has approved donislecel, a new pancreatic islet cellular therapy made from the pancreatic cells of deceased donors, for the treatment of type 1 diabetes among adult patients with severe hypoglycemia. Lantidra
Share on Twitter Share on Facebook Share on Linkedin

FDA approves first cellular therapy to treat type 1 diabetes

Share on Twitter Share on Facebook Share on Linkedin
The FDA has approved donislecel, a new pancreatic islet cellular therapy made from the pancreatic cells of deceased donors, for the treatment of type 1 diabetes among adult patients with severe hypoglycemia. Lantidra
The new therapy, made from the pancreatic cells of deceased donors, is designed to help adult type 1 diabetes with severe hypoglycemia go a year or longer without needing to take insulin. 
READ MORE >

Keto diet could be good for heart failure patients, but many questions remain

A team of specialists from the Cleveland Clinic detailed the potential benefits—and risks—associated with following a ketogenic diet to address heart failure symptoms. The group recommended borrowing heavily from the Mediterranean diet and avoiding heavily processed "keto-friendly" products. 

READ MORE >
Mediterranean diet keto diet
Share on Twitter Share on Facebook Share on Linkedin

Keto diet could be good for heart failure patients, but many questions remain

Share on Twitter Share on Facebook Share on Linkedin
Mediterranean diet keto diet
A team of specialists from the Cleveland Clinic detailed the potential benefits—and risks—associated with following a ketogenic diet to address heart failure symptoms. The group recommended borrowing heavily from the Mediterranean diet and avoiding heavily processed "keto-friendly" products. 
READ MORE >

Abbott awards $2.6M to American Diabetes Association for CGM research

The three-year grant will help the ADA fund two pilot programs and engage with healthcare professionals and other industry leaders.

READ MORE >
Money dollar investments
Share on Twitter Share on Facebook Share on Linkedin

Abbott awards $2.6M to American Diabetes Association for CGM research

Share on Twitter Share on Facebook Share on Linkedin
Money dollar investments
The three-year grant will help the ADA fund two pilot programs and engage with healthcare professionals and other industry leaders.
READ MORE >

Innovate Healthcare thanks our partners for supporting our newsletters.
Sponsorship has no influence on editorial content.

Interested in reaching our audiences, contact our team

*|LIST:ADDRESSLINE|*

You received this email because you signed up for newsletters from Innovate Healthcare.
Change your preferences or unsubscribe here

Contact Us  |  Unsubscribe from all  |  Privacy Policy

© Innovate Healthcare, a TriMed Media brand
Innovate Healthcare

Recent Newsletters

AI is gaining ground, but clinicians run the show | Siemens Healthineers doubles down | Electrophysiologist compensation
News Alert: FDA shares warning about heart valve tech after patient death
Cardiologist pay & productivity are up | FDA clears PE thrombectomy devices | Cardiology tech in spotlight | Gore's new approval
Cardiology salaries on the rise | The climbing costs of care | M&A trends | Siemens Healthineers, J&J make big business moves
Major MRI trends | Blood thinner recalled | When to perform PCI before TAVR | How to build a CCTA program | Steroids & the heart
CMS boosts coverage for heart failure tech | FDA approves CardioMEMS updates | LVADs linked to strokes, other risks
M&A activity in cardiology: Exploring key trends | Cardiac PET vs. SPECT | Doctors support Medicare covering TAVR for AR
Newsletter archive
  • Home
  • News
  • Article Archive
  • Custom Content
  • Webinars
  • Press Releases
  • Content Studio
  • Advertising
  • Submit Press Release
  • Contact Us
  • Terms of Use
  • Privacy Policy
  • Cardiovascular Business
  • HealthExec
  • Radiology Business
  • Press Releases
  • Submit Press Release
© 2026 Innovate Healthcare | All Rights Reserved. | Terms of Use | Privacy Policy
Design by Adaptive Theme
Trimed Popup